Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TPO | P07202 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 3/20 | 0.49 |
| ▸ | ACP1 | P24666 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979895 | 0.86 | MEN1 (0.68) | LMNAMEN1KMT2AHPRT1PNP | |
| SCHEMBL22533355 | 0.83 | MEN1 (0.65) | LMNAMEN1KMT2AHPRT1PNP | |
| SCHEMBL1533549 | 0.80 | PNP (0.77) | LMNAMEN1KMT2APNP | |
| SCHEMBL12795899 | 0.78 | PNP (0.56) | LMNAMEN1KMT2APNPGAA | |
| SCHEMBL9475856 | 0.77 | HPGD (0.59) | LMNAMEN1KMT2AMPOTPO | |
| SCHEMBL21977321 | 0.75 | MPO (0.54) | LMNAMEN1KMT2AHPRT1MPO | |
| SCHEMBL6659204 | 0.74 | ADORA2A (0.74) | SLC29A1 | |
| SCHEMBL24239249 | 0.74 | HPRT1 (0.63) | LMNAMEN1KMT2AHPRT1PNP | |
| SCHEMBL1993930 | 0.74 | HPRT1 (0.63) | LMNAMEN1KMT2AHPRT1PNP | |
| SCHEMBL3126819 | 0.73 | ADORA2A (0.60) | LMNAMEN1KMT2AHPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986480-B2 | Heterocyclic compound | TOHOKU UNIVERSITY (JP) | 2024-05-21 | — | — | US | disclosed |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | LMNA 2733/4885MEN1 3191/4885KMT2A 3485/4885 |
| US-11986480-B2 | Heterocyclic compound | SQSTM1, BECN1, ATG7 | LMNA 2733/4885MEN1 3191/4885KMT2A 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.